Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety and tolerability of human somatic cell nuclear transfer embryonic stem cell derived retinal pigmented epithelial(SCNT-hES-RPE) cellular therapy in patients with advanced dry AMD


Clinical Trial Description

To evaluate the safety and tolerability of the SCNT-hES-RPEs, to assess the number of SCNT-hES-RPE cells to be transplanted in future studies and to evaluate on an exploratory basis potential efficacy endpoints to be used in future studies of SCNT-hES-RPE cellular therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03305029
Study type Interventional
Source CHA University
Contact
Status Enrolling by invitation
Phase Phase 1
Start date May 2016
Completion date April 2019

See also
  Status Clinical Trial Phase
Terminated NCT01674829 - A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD Phase 1/Phase 2
Completed NCT00751361 - Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Phase 4
Completed NCT01344993 - Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration Phase 1/Phase 2
Completed NCT00804102 - Transcorneal Electrical Stimulation Therapy for Retinal Disease N/A
Suspended NCT00541333 - Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration Phase 1
Completed NCT00429936 - Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration Phase 2